Home>Topics>Funds>SPDR S&P Biotech

SPDR S&P Biotech

  1. All
  2. Commentary
  3. ETF Reports
  4. Headlines
  1. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Tue, 2 Sep 2014

    for these products in the U.S. XBI 's 0.35% expense ratio is tied ..... like Amgen and Celgene. Thus, XBI 's average market cap, on a holdings ..... exposure to the industry in one trade. SPDR S & P Biotech XBI offers exposure to the promising

  2. FBT First Trust NYSE Arca Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Tue, 2 Sep 2014

    relative to other biotech ETFs--in particular, SPDR S & P Biotech XBI , which charges 0.35%. FBT's estimated holding ..... biotech companies can consider four other ETFs. SPDR S & P Biotech XBI (0.35% expense ratio) holds a fairly concentrated

  3. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Tue, 2 Sep 2014

    cheaper ETF options exist. For instance, both SPDR S & P Biotech XBI and Market Vectors Biotech ETF BBH charge just 0 ..... seeking exposure solely to biotechs also can consider SPDR S & P Biotech XBI (0.35% expense ratio), which is a fairly concentrated

  4. Today's Market: Red Hot Biotech And Big Pharma Names To Watch

    Headlines

    Fri, 29 Aug 2014

    By Matthew Smith : A busy week is about to come to an end, but not before we have learned a lot about the strength of this market and just how resilient it is. Some will point to the weak volume over the past few sessions, but that is to be expected this time of year. Factoring in that volatility

  5. Competition And Momentum Weighing On Clovis Oncology

    Headlines

    Sat, 23 Aug 2014

    actually been all that bad for biotech, as the S&P Biotech ETF (NYSEARCA: XBI ) has outperformed the S&P 500 by about six or seven points. Whether or not the XBI is a great benchmark for the biotech industry is beside the point, though

  6. Dynamic And Durable Growth (Part 1)

    Headlines

    Thu, 24 Jul 2014

    By Invesco : By Janet Luby Part 1: A Biotech/Pharma Revolution This is the first in a four-part series examining dynamic and durable growth themes that affect the U.S. economy and may present opportunities for investors. The remaining three blog posts will examine the enormous implications of shale

  7. Today's Market: Biotech Names Rallying Today

    Headlines

    Wed, 23 Jul 2014

    players in the sector by buying ETFs, such as the SPDR S & P Biotech ETF (NY XBI ) and the iShares Nasdaq Biotechnology (NASDAQ: IBB ) with our preference being the SPDR S & P Biotech due to it having less exposure to the more speculative

  8. Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?

    Headlines

    Mon, 21 Jul 2014

    By DoctoRx : Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed. Biogen Idec (NASDAQ: BIIB ) fell more than 7% after that statement. Gilead Sciences (NASDAQ: GILD ) fell 5% peak-to-trough. Small ones got dumped big-time. Is it but a passing ...

  9. IHE iShares US Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 5 May 2014

    tracking other health-care subsectors show numbers in the 20% to 25% range. For instance, the equal-weight SPDR S & P Biotech XBI has a five-year volatility of return of 24.5%. Meanwhile, the market-cap-weighted iShares US Healthcare

  10. XPH SPDR S&P Pharmaceuticals ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 5 May 2014

    tracking other health-care subsectors show numbers in the 16% to 25% range. For instance, the equal-weight SPDR S & P Biotech XBI has a five-year volatility of return of 24.2%. Meanwhile, the market-cap-weighted iShares US Healthcare

« Prev123Next »
Content Partners